Cardima to begin Phase III US trial for AF (atrial fibrillation) catheter:
This article was originally published in Clinica
Executive Summary
Cardima has received permission from the US FDA to begin the pivotal Phase III stage of its clinical trial to assess its Revelation Tx microcatheter-based ablation device for treating paroxysmal atrial fibrillation (AF). Data from Phase I and II of the US trial and from European trials and commercial use of the product indicate that about 80% of patients treated with the microcatheter have experienced either total elimination or a significant reduction in their AF, said Fremont, California-based Cardima. The product is already CE-marked for sale in Europe.
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.